Related Experiment Video
Updated: Apr 12, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Isavuconazole: a new extended spectrum triazole for invasive mold diseases
Michelle R Ananda-Rajah1, Dimitrios Kontoyiannis
11Infectious Diseases Unit, Alfred Health, Melbourne, VIC, Australia.
Abstract:
Isavuconazole is the first broad spectrum prodrug triazole with efficacy against invasive fungal diseases including aspergillosis and mucormycosis. Characteristics include linear dose-proportional pharmacokinetics, intravenous and oral formulations allowing therapeutic streamlining, once daily dosing, absence of nephrotoxic solubilizing agents and excellent oral bioavailability independent of prandial status and gastric acidity. An open label noncomparator study demonstrated encouraging results for isavuconazole as primary or salvage therapy for a range of fungi including mucormycosis. Isavuconazole had fewer premature drug discontinuations and adverse events in the eye, hepatobiliary and psychiatry systems than the comparator agent, voriconazole in a randomized double-blind clinical trial. Cross-resistance of isavuconazole best correlates with voriconazole. In vitro resistance is not invariably predictive of clinical failure. Isavuconazole signals progress in pharmacokinetics, bioavailability and toxicity/tolerability supported by clinical efficacy from Phase III trials.
Insights
Isavuconazole offers effective treatment for invasive fungal infections like aspergillosis and mucormycosis. This broad-spectrum antifungal agent demonstrates improved tolerability and pharmacokinetics compared to voriconazole.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Invasive fungal infections pose significant mortality risks.
- Broad-spectrum antifungal agents are crucial for treatment.
- Isavuconazole represents a novel triazole prodrug.
Purpose of the Study:
- To evaluate the efficacy and safety of isavuconazole.
- To compare isavuconazole with voriconazole.
- To assess isavuconazole's pharmacokinetic profile.
Main Methods:
- Open-label, non-comparative study for initial efficacy assessment.
- Randomized, double-blind clinical trial comparing isavuconazole to voriconazole.
- Pharmacokinetic and safety analyses.
Main Results:
- Isavuconazole showed efficacy in treating various fungal infections, including mucormycosis.
- Fewer adverse events and discontinuations were observed with isavuconazole versus voriconazole.
- Isavuconazole exhibits favorable pharmacokinetics, including excellent oral bioavailability and once-daily dosing.
Conclusions:
- Isavuconazole is a promising broad-spectrum antifungal with a favorable safety and tolerability profile.
- Its pharmacokinetic properties support therapeutic streamlining.
- Clinical efficacy supports its use in invasive fungal diseases.
More Related Videos
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
08:45Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Related Concept Videos
Antifungal Agents
Antimicrobial Effectiveness
Endocarditis III: Medical Management
Fungal Phylum Ascomycota
Fungal Group Zygomycota
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...